摘要：Analysis of the leading and emerging biotechnology companies identifies current and future trends in biotherapeutics. The ten leading biotechnology companies are forecast to generate cumulative revenues of US$31.7bn in 2007, with niche therapeutic areas and oncology forecast to account of 31 per cent and 27 per cent of these revenues, respectively. Small molecules are forecast to play a central role in the emerging sector's quest for revenue generation. Indeed small molecules carry the potential to become the dominant technological trajectory in terms of pipeline development, eclipsing antibody-based and rDNA technologies. Critical to the industry's future performance will be the ability of emerging companies to generate sustained businesses, and to validate their newly developed pipelines with the leading biotechnology or pharmaceutical players.
